This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.
This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-CoV-2 comprising a partly codon deoptimized viral genome, SARS-CoV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.
The present disclosure provides a scalable step-wise process for purification of diphtheria toxoid that is faster, and provides reduced process variability in toxoid retention.
The present disclosure provides a scalable step-wise process for purification of tetanus toxoid that is faster, and provides reduced process variability in toxoid retention.
A recombinant monoclonal anti-bovine IgA antibody is disclosed herein. The anti- bovine IgA antibody as disclosed is scFv. The present invention further provides a recombinant vector comprising the polynucleotide encoding the recombinant antibody and a host comprising the vector. The anti-bovine IgA antibody as disclosed herein shows strong binding to bovine IgA antibody. The antibody is useful as a reagent for the detection of bovine IgA in a sample.
A monovalent anti-canine parvovirus antibody is disclosed herein. The anti-canine parvovirus antibody as disclosed is scFv. The present disclosure further provides a recombinant vector and a host comprising the vector. The anti -canine parvovirus antibody as disclosed herein shows strong binding to canine parvovirus. The antibody is useful in development of a composition for treatment or prevention of canine parvovirus.
The present invention relates to generation of monovalent antibody fragment, single chain variable fragment (ScFv) from human immunised library having one antigen binding site that is reactive against the Hepatitis A virus which can be used as a diagnostic tool. The present invention particularly provides monovalent human anti-Hepatitis A antibody fragments and a process of preparation thereof.
The present invention provides recombinant human bivalent diabody against rabies virus capable of recognizing rabies virus glycoprotein and neutralizing rabies viruses and a method for production thereof. The present invention further provides polynucleotide encoding the recombinant bivalent diabody. The bivalent diabody disclosed in the present invention is also useful for quantitation of the rabies virus glycoprotein for evaluating the vaccine quality and predicting the vaccine potency.
The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The present disclosure provides a highly efficient means for differentiating Foot and Mouth Disease Virus (FMDV) infected animals from vaccinated animals. The present disclosure further provides a process for the production of chimeric TVLPs and a diagnostic kit for the determination of specific antibodies of FMDV to differentiate FMDV infected from vaccinated animals. The present disclosure also provides the use of the chimeric TVLPs for diagnostic purposes.
patents
